First National Bank of Elk City	Elk City	Oklahoma.
Bank of the Panhandle	Guymon	Oklahoma.
First National Bank in Marlow	Marlow	Oklahoma.
BancFirst	Oklahoma City	Oklahoma.
First American Bank	Purcell	Oklahoma.
	Quinton	Oklahoma.
First National Bank & Trust Company	Shawnee	Oklahoma.
	Tulsa	Oklahoma.
The First National Bank of Vinita	Vinita	Oklahoma.

Federal Home Loan Bank of San Francisco—District 11

Bank 1440	Phoenix	Arizona.
	Capitola	California.
Bay Federal Credit Union		California.
Xceed Financial Federal Credit Union	El Segundo	
Fremont Bank	Fremont	California.
American First Credit Union	La Habra	California.
Silvergate Bank	La Jolla	California.
Preferred Bank	Los Angeles	California.
Broadway Federal Bank, F.S.B.	Los Angeles	California.
Monterey County Bank	Monterey	California.
Oak Valley Community Bank	Oakdale	California.
Malaga Bank, F.S.B.	Palos Verdes Estates	California.
El Dorado Savings Bank, F.S.B.	Placerville	California.
Bank of Southern California, National Association	Ramona	California.
Bank of San Francisco	San Francisco	California.
CSAA Insurance Exchange	San Francisco	California.
AltaPacific Bank	Santa Rosa	California.
Bank of America California, N.A.	Walnut Creek	California.

Federal Home Loan Bank of Seattle—District 12

Fairbanks	Alaska.
Hagatna	Guam.
Malad	Idaho.
Twin Falls	Idaho.
Absarokee	Montana.
Dillon	Montana.
Helena	Montana.
Kalispell	Montana.
Malta	Montana.
American Fork	Utah.
Salt Lake City	Utah.
Fairfield	Washington.
Port Orchard	Washington.
Seattle	Washington.
Spokane	Washington.
	Hagatna Malad Twin Falls Absarokee Dillon Helena Kalispell Malta American Fork Salt Lake City Fairfield Port Orchard Seattle

II. Public Comments

To encourage the submission of public comments on the community support performance of Bank members, on or before May 8, 2014, each Bank will notify its Advisory Council and nonprofit housing developers, community groups, and other interested parties in its district of the members selected for community support review in the 2014-2015 Review Cycle-2nd Round. 12 CFR 1290.2(b)(2)(ii). In reviewing a member for community support compliance, FHFA will consider any public comments it has received concerning the member. 12 CFR 1290.2(d). To ensure consideration by FHFA, comments concerning the community support performance of members selected for the 2014-2015 Review Cycle—2nd Round must be delivered to FHFA, either by hard-copy mail at the Federal Housing Finance

Agency, Ninth Floor, Housing Mission and Goals (DHMG), 400 Seventh Street SW., Washington, DC 20024, or by electronic mail to *hmgcommunitysupportprogram@ fhfa.gov* on or before the June 9, 2014 deadline for submission of Community Support Statements.

Dated: April 17, 2014.

Melvin L. Watt,

Director, Federal Housing Finance Agency. [FR Doc. 2014–09336 Filed 4–24–14; 8:45 am] BILLING CODE 8070–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

Li Chen, Ph.D., Mount Sinai School of Medicine: Based on evidence and findings of an investigation report by Mount Sinai School of Medicine (MSSM) transmitted to the United States Department of Health and Human Services (HHS), Office of Research Integrity (ORI), in April 2010 and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Li Chen, former Postdoctoral Fellow, Department of Gene and Cell Medicine, MSSM, engaged in research misconduct in research that was supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), grant R01 DK062972 and National

Institute of General Medical Sciences (NIGMS), NIH, grant P20 GM075019 and was submitted in grant applications R01 DK074695 and R01 DK083286 to NIDDK, NIH, P20 GM075019 to NIGMS, NIH, and R01 NS062054 to the National Institute of Neurological Disorders and Stroke (NINDS), NIH.

ORI found that the Respondent intentionally, knowingly, and recklessly fabricated and falsified data reported in four (4) publications, one (1) submitted manuscript, and four (4) grant applications:

• Chen, L., & Woo, S.L.C. "Complete and persistent phenotypic correction of phenylketonuria in mice by site-specific genome integration of murine phenylalanine hydroxylase cDNA." *Proc. Natl. Acad. Sci. U.S.A.* 102(43):15581–15586, October 2005 (hereafter referred to as "*PNAS* 2005").

• Chen, L., Thung, S.N., & Woo, S.L.C. "Metabolic Basis of Sexual Dimorphism in PKU Mice After Genome-targeted PAH Gene Therapy." *Mol. Ther.* 15:1079–1085, June 2007; Retracted in December 2010 (hereafter referred to as "*Mol. Ther.* June 2007").

• Chen, L., & Woo, S.L.C. "Correction in Female PKU Mice by Repeated Administration of mPAH cDNA Using phiBT1 Integration System." *Mol. Ther.* 15:1789–1795, October 2007; Retracted in December 2010 (hereafter referred to as "*Mol. Ther.* Oct. 2007").

• Chen, L., & Woo, S.L.C. "Site-Specific Transgene Integration in the Human Genome Catalyzed by ÖBT1 Phage Integrase." *Hum. Gene Ther.* 19:143–151, February 2008; Retracted in August 2010 (hereafter referred to as "*HGT* 2008").

• Chen, L., Roy, I., Prasad, P.N., & Woo, S.L.C. "Nanoparticle-Based Gene Therapy for Metabolic Disorders: Hepatic Delivery of Minicircle DNA for Complete Correction of Phenylketonuria." Submitted for publication in *Proc. Natl. Acad. Sci. U.S.A.* (hereafter referred to as the "PNAS 2008 manuscript").

• R01 DK074695, "Genome-targeted PAH Gene Integration in PKU Mice and Sexual Dimorphism," Savio L.C. Wood, Ph.D., Principal Investigator (P.I.) (hereafter referred to as "R01 DK074695").

• P20 GM075019, "Growth, Differentiation & Genetic Alteration of Human ES Cells," Gordon M. Keller, Ph.D., P.I. (hereafter referred to as "P20 GM075019").

• R01 NS062054, "Nanoparticlemedicated Gene Therapy for PKU," Savio L. Woo, Ph.D., P.I. (hereafter referred to as "R01 NS062054").

• R01 DK083285, "Nanoparticle-Mediated Gene Therapy PKU," Savio L. Woo, Ph.D., P.I. (hereafter referred to as "R01 DK083285").

The Respondent fabricated figures reporting the chromosomal locations of integration sites, fabricated data reporting the use of polymerase chain reaction (PCR) to determine integration frequencies, falsified data representing the detection of chromosomal translocations in human cells, and fabricated figures by falsely reporting the results of High-Performance Liquid Chromatography (HPLC) assays. The Respondent also falsified experimental data for LacZ stained liver sections and for hematoxylin and eosin (H&E) stained liver sections.

Specifically, ORI finds by a preponderance of the evidence that the Respondent engaged in misconduct in science and research misconduct by intentionally, knowingly, and recklessly:

1. fabricating and/or falsifying nineteen (19) figures by falsely reporting that phenylketonuria (PKU) gene therapy experiments were successfully completed, when the available evidence shows the experiments were not performed; specifically the Respondent:

(a) fabricated figures where DNA sequencing was purportedly used to identify the chromosomal locations of integration sites for the PAH gene in mouse and human cells, reported in seven (7) figures:

- *PNAS* 2005, Figure 2A
- HGT 2008, Figures 3b and 3c
- R01 NS062054, Figures 3 and 20
- R01 DK074695, Figure 6
- R01 DK083286, Figure 17
- P20 GM075019, Figure 4

(b) fabricated data purportedly representing the use of PCR to determine integration frequencies for the phenylalanine hydroxylase (PAH) gene and the secreted embryonic alkaline phosphatase (SEAP) reporter gene, in mouse and human cells, reported in eleven (11) figures:

• PNAS 2005, Figures 2C and 3B

• *Mol. Ther.* June 2007, Figures 2a and 5a

• *Mol. Ther.* Oct. 2007, Figures 2d and 5a

- *HGT* 2008, Figure 4
- R01 NS062054, Figures 4b and 10a
- R01 DK074695, Figure 7b
- R01 DK083286, Figure 2b

(c) falsified figures representing the detection of chromosomal tranlocations in human cells, purportedly determined by PCR in two (2) figures:

- *HGT* 2008, Figure 5a
- R01 NS062054, Figure 21a

2. fabricating the results of HPLC assays to show generally lowered blood levels of phenylalanine after PKU gene therapy and to show liver levels of BH₄ when the Respondent did not have the HPLC data needed to support those claims; specifically the Respondent:

(a) fabricated serum phenylalanine graphs in:

• *PNAS* 2005, Figure 4B; this false data also is presented in R01 DK074695, Figure 10b

• *Mol. Ther.* June 2007, Figure 1a; this false data also is presented in R01 DK074695, Figure 11

• R01 DK083286, Figure 3; this false data also is presented in *Mol. Ther.* June 2007, Figure 3, and R01 NS062054, Figure 7

• *Mol. Ther.* Oct. 2007, Figure 4a; this false data also is presented in R01 NS062054, Figure 9a

• *PNAS* 2008 manuscript, Figure 4

(b) fabricated graphs for BH₄ levels in: *Mol. Ther.* June 2007, Figure 5c;
this false data also is presented in R01

this false data also is presented in R01 NS062054, Figure 8c

3. falsely reporting the results of LacZ stained liver sections by reusing and relabeling an image and claiming that it represents different experiments; specifically, the same image was used to represent mice treated with a nanoplex gene delivery system in R01 NS062054, Figure 14b (right panel), and also to represent a wholly different experiment for mice treated with 10 injections of the phiBT1 integrase system alone in R01 NS062054, Figure 4c (right panel), and *Mol. Ther.* Oct. 2007, Figure 2b (D panel)

4. falsely reporting the results of H&E stained liver sections in R01 NS062054, Figure 6, by using the identical image to represent four (4) different experimental treatments of H&E stained liver sections; specifically the Respondent reused and relabeled one image to represent liver sections from mice that received either 1 or 10 injections, with or without the phiBT1 integrase plasmid.

The Respondent failed to take responsibility for the fabrication and falsification described in ORI's findings.

The following administrative actions have been implemented for a period of three (3) years, beginning on April 11, 2014:

(1) Respondent is debarred from any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement programs of the United States Government referred to as "covered transactions" pursuant to HHS' Implementation (2 CFR part 376 *et seq.*) of Office of Management and Budget (OMB) Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the "Debarment Regulations"); and

(2) Respondent is prohibited from serving in any advisory capacity to PHS,

including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT:

Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453– 8800.

Donald Wright,

Acting Director, Office of Research Integrity. [FR Doc. 2014–09434 Filed 4–24–14; 8:45 am] BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review

The meeting announced below concerns Reducing Youth Exposure to Alcohol Marketing, Special Interest Projects (SIP)14–009, Panel A, initial review.

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting:

Time and Date: 10:00 a.m.–5:00 p.m., May 19, 2014 (Closed).

Place: Teleconference.

Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters for Discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to "Reducing Youth Exposure to Alcohol Marketing, SIP14–009, Panel A, initial review."

Contact Person for More Information: M. Chris Langub, Ph.D., Scientific Review Officer, CDC, 4770 Buford Highway, NE., Mailstop F–80, Atlanta, Georgia 30341, Telephone: (770) 488–3585, *EEO6@cdc.gov*.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2014–09373 Filed 4–24–14; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[Document Identifiers CMS-10517]

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Centers for Medicare & Medicaid Services, HHS. ACTION: Notice.

SUMMARY: The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (the PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information (including each proposed extension or reinstatement of an existing collection of information) and to allow 60 days for public comment on the proposed action. Interested persons are invited to send comments regarding our burden estimates or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

DATES: Comments must be received by June 24, 2014.

ADDRESSES: When commenting, please reference the document identifier or OMB control number (OCN). To be assured consideration, comments and recommendations must be submitted in any one of the following ways:

1. *Electronically*. You may send your comments electronically to *http://www.regulations.gov*. Follow the instructions for "Comment or Submission" or "More Search Options" to find the information collection document(s) that are accepting comments.

2. *By regular mail.* You may mail written comments to the following address: CMS, Office of Strategic Operations and Regulatory Affairs, Division of Regulations Development Attention: Document Identifier/OMB Control Number ____, Room C4–26–05, 7500 Security Boulevard, Baltimore, Maryland 21244–1850.

To obtain copies of a supporting statement and any related forms for the proposed collection(s) summarized in this notice, you may make your request using one of following:

1. Access CMS' Web site address at http://www.cms.hhs.gov/Paperwork ReductionActof1995.

2. Email your request, including your address, phone number, OMB number, and CMS document identifier, to *Paperwork@cms.hhs.gov.*

3. Call the Reports Clearance Office at (410) 786–1326.

FOR FURTHER INFORMATION CONTACT:

Reports Clearance Office at (410) 786–1326.

SUPPLEMENTARY INFORMATION:

Contents

This notice sets out a summary of the use and burden associated with the following information collections. More detailed information can be found in each collection's supporting statement and associated materials (see **ADDRESSES**).

CMS-10517 The Predictive Learning Analytics Tracking Outcome (PLATOTM)

Under the PRA (44 U.S.C. 3501– 3520), federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. The term "collection of information" is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA requires federal agencies to publish a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, CMS is publishing this notice.

Information Collection

1. Type of Information Collection Request: New collection (Request for a new control number); Title of Information Collection: The Predictive Learning Analytics Tracking Outcome (PLATOTM); Use: The Predictive Learning Analytics Tracking Outcome (PLATOTM) is a web-based application tool that will serve as the centerpiece of the advanced analytics initiative with the Centers for Medicare & Medicaid Services (CMS) and Health Integrity, LLC, the National Benefit Integrity